[Cancer-related breakthrough pain].

[1]  Horng-Shiuann Wu,et al.  Definition, prevalence and characteristics of sudden exhaustion: a possible syndrome of fatigue in cancer? , 2013, Supportive Care in Cancer.

[2]  T. Hayes,et al.  Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain , 2009, Current medical research and opinion.

[3]  L. Radbruch,et al.  A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial , 2009, Current medical research and opinion.

[4]  S. Mercadante,et al.  686 EASE OF USE AND PREFERENCE FOR INTRANASAL FENTANYL SPRAY (INFS) VERSUS ORAL TRANSMUCOSAL FENTANYL CITRATE (OTFC) FOR BREAKTHROUGH CANCER PAIN , 2009 .

[5]  V. Ratanatharathorn,et al.  Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. , 2009, Journal of palliative medicine.

[6]  P. Watts,et al.  PecSys: in situ gelling system for optimised nasal drug delivery , 2009 .

[7]  A. Burton,et al.  Fentanyl pectin nasal spray (FPNS) with PecSys®: onset of action, consistency, and acceptability in breakthrough cancer pain (BTCP) , 2009 .

[8]  A. Burton,et al.  Fentanyl pectin nasal spray (FPNS) with PecSys®: efficacy, tolerability, and onset of action in the treatment of breakthrough cancer pain (BTCP) , 2009 .

[9]  C. Reid,et al.  The management of cancer‐related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland , 2009, European journal of pain.

[10]  M. Ashby,et al.  Intranasal sufentanil for cancer-associated breakthrough pain , 2009, Palliative medicine.

[11]  S. Abram.  Intrathecal Treatment in Cancer Patients Unresponsive to Multiple Trials of Systemic Opioids , 2009 .

[12]  A. Finn,et al.  Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate , 2009, Clinical drug investigation.

[13]  Justin Stark,et al.  Absorption and tolerability of BEMA (BioErodible MucoAdhesive) fentanyl in cancer subjects with grade 1 mucositis , 2008 .

[14]  A. Finn,et al.  191) Dose linearity and absolute bioavailability of BEMA (BioErodible MucoAdhesive) fentanyl in healthy volunteers , 2008 .

[15]  Kirk A. Overhoff,et al.  Review of the TAIFUN® Multidose Dry Powder Inhaler Technology , 2008 .

[16]  P. Robertson,et al.  Bioequivalence Following Buccal and Sublingual Placement of Fentanyl Buccal Tablet 400 μg in Healthy Subjects , 2008, Clinical drug investigation.

[17]  P. Fine,et al.  Fentanyl buccal tablet. , 2008, Drugs of today.

[18]  C. Stiles,et al.  Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. , 2007, Journal of palliative medicine.

[19]  P. Robertson,et al.  Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate , 2007, Journal of clinical pharmacology.

[20]  William Lavelle,et al.  Vertebroplasty and kyphoplasty. , 2007, Anesthesiology clinics.

[21]  E. Espinosa,et al.  Clinical Role of Sm-153 EDTMP in the Treatment of Painful Bone Metastatic Disease , 2006, Clinical nuclear medicine.

[22]  J. Messina,et al.  Fentanyl effervescent buccal tablets , 2006 .

[23]  L. Vlahos,et al.  Oral Transmucosal Fentanyl Citrate: Overview of Pharmacological and Clinical Characteristics , 2006, Drug delivery.

[24]  A. Wagstaff,et al.  Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. , 2006, Drugs.

[25]  R. Fainsinger,et al.  A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain , 2005, Palliative medicine.

[26]  T. Hedner,et al.  Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. , 2005, British journal of clinical pharmacology.

[27]  P. S. Sillevis Smitt,et al.  The "pain pen" for breakthrough cancer pain: a promising treatment. , 2005, Journal of pain and symptom management.

[28]  M. Darwish,et al.  Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers , 2005, Clinical pharmacokinetics.

[29]  S. Mercadante,et al.  Optimization of opioid therapy for preventing incident pain associated with bone metastases. , 2004, Journal of pain and symptom management.

[30]  E. Zecca,et al.  Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey , 2004, Palliative medicine.

[31]  L. Harrison,et al.  Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis , 2004, Supportive Care in Cancer.

[32]  E. Kharasch,et al.  Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients , 2003, Pain.

[33]  Susanne Bredenberg,et al.  In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  S. Archer,et al.  Pharmacokinetics and Bioavailability of Single-Dose Intranasal Hydromorphone Hydrochloride in Healthy Volunteers , 2003, Anesthesia and analgesia.

[35]  M. Johnston,et al.  Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. , 2003, International journal of radiation oncology, biology, physics.

[36]  J. Ashley,et al.  Description and predictors of direct and indirect costs of pain reported by cancer patients. , 2003, Journal of pain and symptom management.

[37]  A. Wilcock,et al.  Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer. , 2002, Journal of pain and symptom management.

[38]  E. Kharasch,et al.  Disposition of nasal, intravenous, and oral methadone in healthy volunteers , 2002, Clinical pharmacology and therapeutics.

[39]  M. Nabal,et al.  Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. , 2002, Journal of pain and symptom management.

[40]  M. Ashby,et al.  Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain. , 2002, Journal of Pain and Symptom Management.

[41]  R. Portenoy,et al.  A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. , 2002, The journal of pain : official journal of the American Pain Society.

[42]  E. Bruera,et al.  The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients. , 2001, Journal of pain and symptom management.

[43]  L. Hart,et al.  Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. , 2001, Journal of pain and symptom management.

[44]  G. Zeppetella.  Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study , 2001, Palliative medicine.

[45]  E. Kalso,et al.  Morphine and alternative opioids in cancer pain: the EAPC recommendations , 2001, British Journal of Cancer.

[46]  R. Lennard,et al.  The prevalence of episodic pain in cancer: a survey of hospice patients on admission , 2001, Palliative medicine.

[47]  S. Collins,et al.  Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. , 2000, Journal of pain and symptom management.

[48]  R. Portenoy,et al.  Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study , 1999, PAIN.

[49]  P. Fine,et al.  Characterization of breakthrough pain by hospice patients and their caregivers. , 1998, Journal of pain and symptom management.

[50]  J. Farrar,et al.  Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. , 1998, Journal of the National Cancer Institute.

[51]  W. Meissner,et al.  Pharmacokinetics of intranasal alfentanil. , 1995, Journal of clinical anesthesia.

[52]  M. Ashburn,et al.  Absorption and bioavailability of oral transmucosal fentanyl citrate. , 1991, Anesthesiology.

[53]  M. Schroeder.  Neurolytic nerve block for cancer pain. , 1986, Journal of pain and symptom management.

[54]  Richard Carter,et al.  Breakthrough , 1966 .